PD-L1 as a Potential Therapeutic Target to Immune Checkpoint Blockade in Cervical Cancer: A Review of the Literature

Humairah Medina Liza Lubis, Asma Dwi Nantika Sitompul, Basrah Bee Binte Shaik Hussain, Annissa Ambaravista Nasution

Abstract


Cervical cancer (CC) is still one of the most common malignant tumors in women worldwide. Malignant tumors are known for evading immune surveillance. In cervical lesions, the mechanism has received less attention. Evasion of immune surveillance through a variety of mechanisms; one of which is the immune checkpoint pathway has attracted interest because it can be therapeutically targeted, the programmed cell death 1 (PD-1) pathway that tumor cells use to block antitumoral immune responses. Increasing the prevalence of PD-L1 expression in up to 80% of cervical malignancies, there is a significant indication using immunotherapy to maintain the immune response against malignancies. The purpose of this literature review is to examine the potential role of immune checkpoint inhibitors in the treatment of cervical neoplastic lesions, by reviewing articles on cervical intraepithelial neoplasia (CIN) and cervical cancer that carried out histopathological and immunohistochemical examination PD-L1 as well as immunotherapy treatment with anti-PD-L1. There were 10 articles were found to be associated with anti-PD-1/PD-L1 immunotherapy. In conclusion, PD-L1 is a potential therapeutic target in cervical cancer


Keywords


PD-L1, PD-1, cervical intraepithelial neoplasia, cervical cancer, immunotherapy, immune checkpoint inhibitors

Full Text:

PDF

References


WHO. Comprehensive Cervical Cancer Control. Geneva. 2014;366–78.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

Rachmadi L, Siregar NC, Kanoko M, Andrijono A, Bardosono S, Suryandari DA, et al. Role of cancer stem cell, apoptotic factor, DNA repair, and telomerase toward radiation therapy response in stage IIIB cervical cancer. Oman Med J. 2019;34(3):224–30.

Clifford GM, Tully S, Franceschi S. Carcinogenicity of human papillomavirus (HPV) types in HIV-positive women: A meta-analysis from HPV infection to cervical cancer. Clin Infect Dis. 2017;64(9):1228–35.

Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Heal. 2020;8(2):e191–203.

Fang J, Zhang H, Jin S. Epigenetics and cervical cancer: From pathogenesis to therapy. Tumor Biol. 2014;35(6):5083–93.

Bhat P. Human papillomavirus E7 oncoprotein expression by keratinocytes alters the cytotoxic mechanisms used by CD8 T cells. Oncotarget [Internet]. 2018;9(5):6015–27. Available from: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85040674414&origin=inward

Cervical Intraepithelial Squamous Cell Lesion - PubMed.

Liu Z, Shi H. Prognostic role of squamous cell carcinoma antigen in cervical cancer: A meta-analysis. Dis Markers. 2019;2019.

Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, et al. Cervical cancer neoantigen landscape and immune activity is associated with human papillomavirus master regulators. Front Immunol. 2017;8(JUN):1–8.

Wang RF, Wang HY. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res [Internet]. 2017;27(1):11–37. Available from: http://dx.doi.org/10.1038/cr.2016.155

Sales KJ. Human Papillomavirus and Cervical Cancer. Cancer Inflamm Mech Chem Biol Clin Asp. 2014;40(5):165–80.

Yang W, Song Y, Lu YL, Sun JZ, Wang HW. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology. 2013;139(4):513–22.

Meng Y. PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. J Cancer [Internet]. 2018;9(16):2938–45.

Reddy OL, Shintaku PI, Moatamed NA. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. Diagn Pathol. 2017;12(1):1–11.

Nicol AF, de Andrade CV, Gomes SC, Brusadelli MG, Lodin HM, Wells SI, et al. The distribution of novel biomarkers in carcinoma-in-situ, microinvasive, and squamous cell carcinoma of the uterine cervix. Ann Diagn Pathol [Internet]. 2019;38:115–22.

Yang W, Lu YP, Yang YZ, Kang JR, Jin YD, Wang HW. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status. J Obstet Gynaecol Res. 2017;43(10):1602–12.

Saglam O, Zhou J, Wang X, Conejo-Garcia JR. PD-L1 expression correlates with young age and CD8+ TiL density in poorly differentiated cervical squamous cell carcinoma. Int J Gynecol Pathol. 2020;39(5):428–35.

Ngoi NYL, Heong V, Lee XW, Huang YQ, Thian YL, Choo BA, et al. Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. Gynecol Oncol Reports. 2018;24(January):1–5.

Chen H, Xia B, Zheng T, Lou G. Immunoscore system combining CD8 and PD-1/PD-L1: A novel approach that predicts the clinical outcomes for cervical cancer. Int J Biol Markers [Internet]. 2020;35(1):65–73.

Rotman J. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential. Front Immunol [Internet]. 2020;11.

Chinn Z, Stoler MH, Mills AM. PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy. Histopathology. 2019;74(2):256–68.

Liang Y, Yu M, Zhou C, Zhu X. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy. Diagn Pathol. 2020 Jun 3;15(1).




DOI: http://dx.doi.org/10.30596%2Fbf.v7i1.8926

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

BULETIN FARMATERA

Gedung Kampus 1 Fakultas Kedokteran Universitas Muhammadiyah Sumatera Utara | UMSU

Lantai II,Laboratorium Farmakologi dan Terapi FK UMSU-Jalan Gedung Arca No. 53 Medan-Sumatera Utara ,

Kode Pos 20217 Kontak: 0812-6208-2844,E-mail: farmatera@umsu.ac.id


 
Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
View My Stats Buletin Farmatera